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The transcription factor ERG regulates a low shear
stress-induced anti-thrombotic pathway
in the microvasculature
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Endothelial cells actively maintain an anti-thrombotic environment; loss of this protective
function may lead to thrombosis and systemic coagulopathy. The transcription factor ERG is
essential to maintain endothelial homeostasis. Here, we show that inducible endothelial ERG
deletion (ErgiEC-KO) in mice is associated with spontaneous thrombosis, hemorrhages
and systemic coagulopathy. We find that ERG drives transcription of the anticoagulant
thrombomodulin (TM), as shown by reporter assays and chromatin immunoprecipitation.
TM expression is regulated by shear stress (SS) via Krüppel-like factor 2 (KLF2). In vitro, ERG
regulates TM expression under low SS conditions, by facilitating KLF2 binding to the TM
promoter. However, ERG is dispensable for TM expression in high SS conditions. In ErgiEC-KO
mice, TM expression is decreased in liver and lung microvasculature exposed to low SS
but not in blood vessels exposed to high SS. Our study identifies an endogenous, vascular
bed-specific anticoagulant pathway in microvasculature exposed to low SS.
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Hemostasis is a physiological mechanism, which aims tomaintain vessel integrity through the formation of a bloodclot after injury. A crucial function of the healthy endo-
thelium is to maintain a constitutive anti-thrombotic state via the
fine regulation of many procoagulant and anticoagulant genes1,2.
Clinical evidence supports the concept that vascular bed-specific
pathways balance local hemostasis and thrombosis, with differ-
ences between arterial, venous and microvascular beds3,4, sug-
gesting possible advantages in vascular-bed specific therapeutic
approaches. However, the molecular basis for such specificity is
poorly understood.
Amongst the multiple procoagulant and anticoagulant path-
ways controlled by endothelial cells (EC), thrombomodulin (TM)
is a key player in the regulation of coagulation and thrombosis.
TM is widely expressed by EC of intact vessels and exerts anti-
coagulant properties by potentiating activation of protein C; it also
has anti-fibrinolytic and anti-inflammatory functions5. In vivo,
60% of the mice with genetic constitutive deletion of TM in EC
survive beyond birth, but show impairment of protein C activation
and succumb to spontaneous thrombosis, resulting in consump-
tion of coagulation factors, coagulopathy and generalised bleed-
ing6. In line with its anticoagulant and anti-inflammatory roles,
TM has been implicated in multiple inflammatory and ischemic
pathologies. Polymorphisms in the TM gene have been reported to
be associated with increased risk of venous thromboembolism7,
bleeding disorder8, coronary artery disease9, atypical hemolytic-
uremic syndrome10 and atherosclerotic disease11. TM expression
was shown to be downregulated on EC overlying the athero-
sclerotic plaque12. Finally, recombinant soluble TM therapy has
been shown to be beneficial in treating sepsis and suspected dis-
seminated intravascular coagulation13,14.
Previous studies have demonstrated that different external sti-
muli are able to transcriptionally regulate TM. Laminar shear stress
(SS) has been shown to upregulate TM expression15,16, whereas
inflammatory cytokines such as TNF-α repress TM expression via
the transcription factor (TF) NF-κB17,18. Multiple TF have been
implicated in the regulation of TM expression, including Krüppel-
like factor 2 (KLF2)5,19. KLF2 has been shown to regulate TM
levels in EC in static, low and high SS conditions20,21. Upregulation
of TM expression by high SS, mediated by KLF2 (refs20–22), is an
important protective anti-thrombotic and anti-atherosclerotic
mechanism in large arteries23–25. However, unlike loss of endo-
thelial TM, in vivo deletion of KLF2 in mice leads to a modest
decrease in TM expression and is not sufficient to cause sponta-
neous thrombosis, showing that KLF2 requires the cooperation
with other TF to regulate TM levels and exert its anti-thrombotic
effects26, possibly in selected vascular beds.
The TF ETS-related gene (ERG) is the most abundant member
of the E-26 transformation specific (ETS) family27 in adult dif-
ferentiated EC, expressed in all vascular beds28,29. Multiple studies
have described the essential role of ERG in the endothelium
(reviewed previously27). ERG regulates vascular development and
angiogenesis through pathways including Notch and Wnt signal-
ling. In the adult, ERG promotes vascular homeostasis through
multiple processes27,30–33. ERG represses vascular inflammation in
healthy endothelium, through inhibition of NF-κB p65 binding to
the promoters of pro-inflammatory genes34,35. Moreover, ERG
protects the endothelium from endothelial-to-mesenchymal tran-
sition (EndMT), a process associated with chronic inflammation
and tissue damage in diseases such as end-stage liver fibrosis36.
Given its multiple homeostatic functions, we hypothesise that
ERG may have an anti-thrombotic effect in EC, thus protecting
blood vessels from spontaneous clot formation. In this study, we
show that inducible chronic endothelial-specific deletion of ERG
in adult mice leads to systemic coagulopathy with spontaneous
thrombosis and/or hemorrhages in selected vascular beds. We
find that ERG regulates TM expression in vivo and that treatment
with recombinant TM fusion protein partly rescues the throm-
botic phenotype observed in ERG-deficient mice. In vitro, we
demonstrate that ERG binds to and transactivates the TM pro-
moter. We identify an ERG-KLF2 complex which cooperates in
driving TM expression. ERG facilitates KLF2 chromatin access,
DNA binding and transactivation of the TM promoter. Inter-
estingly, this pathway is selective for low SS conditions both
in vitro and in vivo. These results identify a low SS-dependent
transcriptional pathway providing protection from spontaneous
thrombosis in the microvasculature.
Results
ERG deletion in mice results in thrombosis and coagulopathy.
Previous studies have shown that deletion of endothelial ERG in
adult mice causes defective angiogenesis, loss of endothelial
homeostasis and enhanced tissue inflammation in multiple
organs27,37. To investigate whether ERG protects EC from
thrombosis in vivo, we used adult mice with inducible endothelial
deletion of ERG (ErgiEC-KO)30,33. ErgiEC-KO mice were injected
with tamoxifen at 6–8 weeks old and analysed 30 and 45 days
after injection. Effective downregulation of ERG expression post-
tamoxifen injection was confirmed by qPCR on liver and lung
lysates (Supplementary Fig. 1a, b). Histological analysis of mul-
tiple tissues revealed the presence of hemorrhages in liver and
lung in ErgiEC-KO mice, as shown by H&E staining (Fig. 1a, b) and
Masson’s Trichrome (Supplementary Fig. 1c). Histological ana-
lysis also showed the presence of spontaneous clots in the liver
(Fig. 1c), in 78% (7/9) and 100% (4/4) of ErgiEC-KO mice, at 30
and 45 days post-tamoxifen injection, respectively. No clots were
identified in lung, brain or kidney tissues. Immunofluorescence
(IF) microscopy confirmed spontaneous intravascular thrombi in
liver blood vessels, with high fibrinogen/fibrin content (Fig. 1d)
and platelet aggregates (Fig. 1e), demonstrating that endothelial
ERG protects from thrombosis in the liver.
To determine whether endothelial ERG impacts the coagula-
tion cascade, a thrombin generation assay was performed on
mouse plasma from ErgiEC-KO mice and littermate control mice
(Supplementary Fig. 1d–f). The data showed no significant
change in the endogenous thrombin potential (ETP) (Supple-
mentary Fig. 1e), but a significant increase in thrombin maximum
peak height (Supplementary Fig. 1f). Interestingly, mice generat-
ing the highest concentration of thrombin in plasma showed the
most pronounced thrombotic phenotype in the liver.
Flow cytometry performed 30 and 45 days post-tamoxifen
(Fig. 1f and Supplementary Fig. 1g, respectively), revealed a
significant decrease in platelet counts in ErgiEC-KO mice; expression
of the platelet marker GP1bβ was unchanged (Supplementary
Fig. 1h). Crucially, analysis of mouse plasma 30 days post tamoxifen
showed decreased fibrinogen concentration (Fig. 1g) associated with
elevated D-dimer (Fig. 1h) and thrombin-antithrombin (TAT)
complex (Fig. 1i) levels in ErgiEC-KO mice; these findings are
indicative of coagulopathy. Notably, the penetrance and severity of
the phenotype in ErgiEC-KO mice appeared to be heterogeneous and
variable (Supplementary Fig. 2a, b).
These data show that the endothelial TF ERG is essential to
protect from spontaneous thrombosis in selected vascular beds.
Deletion of ERG disrupts regulation of coagulation, leading to a
coagulopathy associated with thrombosis and/or bleeding in liver
and lung.
ERG controls expression of multiple regulators of coagulation.
To investigate the molecular mechanisms through which ERG
exerts its anti-thrombotic function, we analysed the global tran-
scriptome profile of ERG-deficient HUVEC38 and identified
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multiple genes directly or indirectly involved in the regulation of
coagulation as putative ERG transcriptional targets. These genes
were validated by qPCR in HUVEC (Fig. 2a). Interestingly,
in vivo analysis showed a tissue-specific pattern in the ERG-
dependent regulation of hemostatic genes (including FVIII, PAI1
and eNOS) by ERG (Fig. 2b, c). The most consistently regulated
ERG target gene, both in vivo and in vitro, is TM. TM mRNA was
significantly downregulated in both liver and lung lysates from
ERG-deficient mice (Fig. 2d, e). This was not due to the loss of
vasculature, since expression of endothelial markers (CD31,
VWF) in lung and liver tissues was not significantly different in
ErgiEC-KO mice compared to control (Fig. 2b, c). Immunoblotting
of lung lysates from ErgiEC-KO mice confirmed that TM protein
was significantly downregulated compared to control mice
(Fig. 2f). These findings suggest that ERG may regulate multiple
procoagulant and anticoagulant genes in a tissue-specific manner
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and points to TM as a key candidate for the anti-thrombotic
effects of ERG.
Thrombomodulin treatment rescues ErgiEC-KO mice pheno-
type. To test whether the thrombotic phenotype observed in
ErgiEC-KO mice was due to the decrease in TM expression, we
used a mouse recombinant TM fusion protein targeting red blood
cells (RBC-TM)39 to restore TM protein activity in vivo. RBC-TM
has been shown to have a longer half-life and to confer more
durable and potent protection from thrombosis in vivo compared
to soluble non-targeted thrombomodulin (sTM)39. The ability of
RBC-TM to generate activated protein C (APC) was confirmed
in vitro (Supplementary Fig. 3a). Plasma was collected from adult
control and ErgiEC-KO mice (25 days post-tamoxifen injection)
before and after (6 h) injection of RBC-TM (4mg per kg, intra-
venous route). Confirmation of ERG deletion and decrease in TM
levels were assessed on liver (Fig. 3a and Supplementary Fig. 3b,
d) and lung (Fig. 3b and Supplementary Fig. 3c, e) tissues. Cru-
cially, acute treatment with RBC-TM in ErgiEC-KO mice was able
to rescue TAT levels (Fig. 3c), an early systemic plasma marker
for coagulopathy/thrombosis with short half-life (45 mins). As
expected, treatment with RBC-TM for 6 h was not sufficient to
correct levels of D-dimer (Fig. 3d) and fibrinogen (Fig. 3e), which
are circulating biomarkers of coagulopathy that emerge later and
have longer half-lives. These data show that an acute treatment
with RBC-TM is able to significantly rescue the coagulopathy
observed in ErgiEC-KO mice.
ERG regulates thrombomodulin expression in endothelial cells.
We used in vitro models to investigate the mechanisms through
which ERG controls TM expression. Inhibition of ERG expres-
sion in HUVEC by siRNA treatment, for 12, 24 and 48 h, caused
a decrease in TM mRNA (Fig. 4a and Supplementary Fig. 4a) and
protein expression, assessed by immunoblotting (Fig. 4b, c and
Supplementary Fig. 4b) and IF microscopy (Fig. 4d, e), compared
to control siRNA. Consistently, ERG inhibition via a second
siRNA sequence confirmed downregulation of TM mRNA
expression levels (Supplementary Fig. 4c). ERG also regulates TM
expression at the mRNA and protein levels in microvascular EC,
in both human dermal microvascular EC (HDMEC) (Supple-
mentary Fig. 4d and Fig. 4d) and human dermal blood EC
(HDBEC) (Fig. 4e). Conversely, ERG overexpression (Supple-
mentary Fig. 4e, f) significantly increased TM expression (Fig. 4f)
in HUVEC.
TM is a key regulator of thrombin-mediated activation of the
natural anticoagulant APC5. To investigate whether the regula-
tion of TM expression by ERG results in regulation of its
function, we conducted a protein C activation assay on HUVEC
treated with control or ERG siRNA and measured the production
of APC over time. In line with decreased TM expression, ERG-
deficient cells (Supplementary Fig. 4g, h) showed reduced
generation of APC after 30 min of incubation with protein C,
with a maximum reduction at the 60 min time point compared to
siCtrl cells (Fig. 4g).
These results demonstrate that ERG regulates TM levels and
thus the TM-protein C system in EC.
ERG transcriptionally regulates thrombomodulin expression.
We investigated the molecular mechanisms by which ERG
induces TM expression in EC. Bioinformatic analysis of the
human TM gene locus revealed the presence of highly conserved
ERG DNA binding motifs in the promoter region (Fig. 5a and
Supplementary Fig. 5a–c). Comparative analysis of chromatin
immunoprecipitation sequencing (ChIP-seq) data for markers of
active promoters (Histone marks H3K4Me3/H3K27Ac and RNA
pol II) in HUVEC (available from ENCODE Consortium)40
showed that the location of these marks correlates with the
position of the putative ERG binding sites (Fig. 5a). Data from
ERG ChIP-sequencing41 (Fig. 5a and Supplementary Fig. 5a; ERG
binding peak) and ChIP-qPCR (Fig. 5b, TM promoter regions R1
and R2; sequence of ERG binding peak shown in Supplementary
Fig. 5c) confirmed ERG binding to the TM promoter but not in a
negative control region distal to the ERG binding peak (Fig. 5b,
TM negative control). Specificity of the ERG antibody was con-
firmed in ERG-deficient HUVEC (Fig. 5b). Functionality of the
ERG binding sites (EBS; A/CGGAA) (Supplementary Fig. 5b)
present on the proximal TM promoter was shown by luciferase
reporter assays (sequence of the TM promoter construct shown in
Supplementary Fig. 6). ERG overexpression resulted in transac-
tivation of TM wild-type (TM WT) promoter in HUVEC
(Fig. 5c); mutation of the two EBS located upstream the tran-
scription start site (TSS) of the TM gene were sufficient to
abrogate this signal, showing that these EBS are functional and
are responsible for ERG’s ability to drive TM (Fig. 5c and Sup-
plementary Fig. 6).
The acetyltransferase p300 has been shown to bind to the TM
promoter and activate its expression18. Pharmacological inhibi-
tion of p300 in HUVEC, resulting in decreased global levels of
histone 3 lysine (K) 27 acetylation (H3K27Ac) (Supplementary
Fig. 7a), led to a decrease in H3K27Ac occupancy on the TM
promoter (Fig. 5d) and a decrease in TM mRNA levels
(Supplementary Fig. 7b). We have recently shown that ERG is
involved in p300 recruitment and acetylation of H3K27 on super-
enhancers associated with endothelial cell-specific genes41. In line
with this concept, we showed that ERG deficient-HUVEC have
reduced p300 binding to the TM promoter region (Fig. 5e,
regions R1 and R2). Deletion of ERG also led to a significant
decrease in H3K27Ac occupancy, in agreement with a reduction
in open and active chromatin (Fig. 5f, regions R1 and R2),
Fig. 1 Endothelial-specific deletion of ERG in adult mice results in thrombosis and coagulopathy. a, b Representative images of H&E staining in a liver and
b lung sections from ErgiEC-KO and Ergfl/fl mice showing the presence of extravasated red blood cells (black arrows) in ErgiEC-KO mice, 30 days after
tamoxifen injection. Scale bar: 100 µm for top panels and 50 µm for bottom panels. c Liver sections from ErgiEC-KO and Ergfl/fl mice imaged following H&E
staining, 30 and 45 days after tamoxifen injection, revealed the presence of spontaneous thrombi in liver from ErgiEC-KO mice, as shown by clots (black
arrows) partially occluding veins. Scale bar 50 µm. d, e Liver sections from ErgiEC-KO mice, 30 days after tamoxifen injection, stained with d an anti-fibrin/
fibrinogen (green) antibody and e a platelet marker (CD41 antibody, green) confirmed the presence of clots (yellow arrowheads) with high fibrinogen
content and platelet aggregates in veins (V) and in sinusoids. Tissues are co-stained for CD31 to visualise blood vessels (magenta); nuclei are identified by
DAPI (blue). Scale bar 50 µm. f Platelet counts (Platelets x 103 per μl expressed as % of control mice) were determined on plasma from ErgiEC-KO and Ergfl/fl
mice, 30 days post tamoxifen (n= 8 per genotype). g Fibrinogen concentration (µg per mL) was measured on plasma from ErgiEC-KO and Ergfl/fl mice,
30 days post tamoxifen, using mouse Fibrinogen ELISA kit (n= 8 per genotype). h D-dimer concentration (ng per mL) was measured on plasma from
ErgiEC-KO and Ergfl/fl mice, 30 days post tamoxifen, using mouse D-dimer ELISA kit (n= 8 per genotype). i Thrombin-antithrombin (TAT) complex
concentration (ng per µL) was measured on plasma from ErgiEC-KO and Ergfl/fl mice, 30 days post tamoxifen, using mouse TAT ELISA kit (n= 8 per
genotype). All graphical data are mean ± s.e.m., *P < 0.05, **P < 0.01, ***P < 0.001, Student’s t-test. Source data are provided as a Source Data file
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suggesting that ERG directly affects chromatin accessibility at the
TM promoter. These data demonstrate that ERG binds to the TM
promoter and directly drives TM expression in EC, through p300
recruitment, acetylation of H3K27 and opening of the chromatin
at the TM promoter region.
ERG cooperates with KLF2 to drive thrombomodulin expres-
sion. The TF KLF2 has been identified as a key regulator of TM
expression in EC20. Analysis of the ERG bound sequence on the
TM promoter revealed the presence of adjacent ERG and KLF2
binding sites close to the TSS (Supplementary Fig. 5c). Thus, we
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investigated whether ERG and KLF2 cooperate in EC to promote
TM expression.
Single ERG or KLF2 siRNA treatment or a combination of the
two led to a comparable decrease in TM mRNA expression
(Supplementary Fig. 8a) or protein levels (Supplementary Fig. 8b,
c), showing no additive effect. ERG siRNA did not affect KLF2
mRNA (Supplementary Fig. 8d) and protein levels (Supplemen-
tary Fig. 8e); similarly, KLF2 siRNA did not affect ERG levels
(Supplementary Fig. 8a–c). However, inhibition of KLF2 expres-
sion caused a significant decrease in ERG’s ability to drive TM
promoter activity (Fig. 6a) and to promote TM expression
(Supplementary Fig. 8f). Moreover, inhibition of ERG expression
caused a significant decrease in the KLF2-dependent transactiva-
tion of the TM promoter and of TM expression (Fig. 6b and
Supplementary Fig. 8g, h). Finally, co-expression of ERG and
KLF2 significantly increased transactivation of the TM promoter
compared to ERG or KLF2 alone (Fig. 6c). These findings indicate
that ERG and KLF2 co-operate in driving TM expression.
Interestingly, mutations of the two ERG binding sites (EBS)
upstream of the TSS, which abolished ERG-dependent transacti-
vation (see Fig. 5c), also led to a complete loss of KLF2
transactivation ability (Fig. 6d) suggesting that ERG binding to
DNA is required for KLF2 transcriptional activity. ChIP-qPCR
analysis showed binding of ERG and KLF2 to the same promoter
regions (Fig. 6e, f, regions R1 and R2,). Inhibition of KLF2
expression in HUVEC had no effect on ERG enrichment on the
TM promoter region (Fig. 6e, regions R1 and R2). However, ERG
deletion led to a significant reduction in KLF2 occupancy on the
TM promoter (Fig. 6f, regions R1 and R2), showing that ERG is
required for KLF2 interaction with the TM promoter.
These data suggested that the two proteins might interact. We
tested this hypothesis in HUVEC, using proximity ligation assay
(PLA); this revealed that ERG and KLF2 bind and form a
complex located in the nucleus (Fig. 6g and Supplementary
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Fig. 9a–c). These data suggest a model of cooperativity where, in
homeostatic conditions, ERG promotes opening of the chromatin
at the TM promoter via p300 recruitment and supports KLF2
recruitment to DNA via direct interaction (Fig. 6h).
ERG regulates thrombomodulin in low shear stress conditions.
Although expressed in EC under static conditions in vitro,
KLF2 and TM are important flow-responsive genes: laminar
shear stress (SS) upregulates expression of KLF2, which then
promotes increased TM expression15,21. Whether ERG is a
flow-responsive TF is unknown. We first interrogated the effect
of low (5 dynes per cm2) and high (20 dynes per cm2) laminar
SS on ERG and KLF2 protein levels in HUVEC. As expected,
KLF2 protein levels were upregulated in HUVEC exposed to
low and high SS compared to static conditions; in contrast, ERG
protein levels were unaffected by SS (Fig. 7a). ERG-KLF2
complex formation was increased under low SS compared to
b
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static conditions; high SS did not further increase this inter-
action (Fig. 7b).
We next investigated the role of ERG in the regulation of TM
expression in static versus low and high SS conditions in HUVEC
treated with either ERG or control siRNA. As expected, KLF2 and
TM mRNA levels were upregulated in HUVEC exposed to SS
compared to static conditions, whilst ERG mRNA levels were
unaffected (Fig. 7c). Crucially, whilst high SS induced upregula-
tion of TM expression in ERG-deficient cells, low SS was not able
to induce TM upregulation in ERG-deficient cells (Fig. 7c),
indicating that ERG controls TM expression selectively in
conditions of low SS and is dispensable for the high SS-
dependent regulation of TM. These results show that the
cooperation between ERG and KLF2 is essential for TM
expression specifically in low SS conditions and suggest that
other partners/pathways support KLF2-dependent transcription
in high SS conditions.
HUVEC are the most widely used EC model in vitro but do not
recapitulate all the properties of EC from different vascular beds.
Therefore, to investigate the role of ERG in the regulation of TM
in EC from microvascular or arterial origins, we conducted flow
experiments on human microvascular EC (HDBEC) (Fig. 7d) and
human aortic endothelial cells (HAEC) (Supplementary Fig. 10).
The experiments on HDBEC showed similar results compared to
HUVEC, demonstrating that ERG regulates TM expression
specifically in low SS conditions also in microvascular EC
(Fig. 7d). However, loss of ERG in HAEC did not affect low
and high SS-induced upregulation of TM expression (Supple-
mentary Fig. 10), indicating that ERG is not involved in the
regulation of TM expression in these cells. These data indicate the
presence of distinct molecular mechanisms of gene regulation in
EC from different vascular beds. Interestingly, these differences
are retained ex vivo, possibly via epigenetic memory of the cells
being exposed to high SS in vivo.
High laminar SS has been shown to mediate chromatin
remodelling by inducing acetylation of histone marks, thus
promoting flow-dependent regulation of gene expression42. We
have recently shown that ERG is required for acetylation of
H3K27 in HUVEC in static conditions41; this was confirmed by
decreased levels of H3K27Ac, assessed by IF microscopy, in ERG-
deficient HUVEC (Fig. 7e). Here, we asked whether ERG
promotes chromatin remodelling and accessibility under different
SS conditions using H3K27Ac global levels as a readout. As
expected, high SS increased levels of H3K27Ac compared to low
SS (Fig. 7e). Interestingly, H3K27Ac levels were significantly
decreased in ERG-siRNA treated cells exposed to low SS
compared to control HUVEC, but were not affected by the loss
of ERG in high SS conditions (Fig. 7e). These data show that ERG
is required for chromatin accessibility in low SS conditions but is
not required under high SS.
ERG controls thrombomodulin expression in microvascular
beds. Finally, we investigated whether ERG regulates TM
expression in EC in vivo, using adult ErgiEC-KO and control mice.
IF microscopy analysis of liver and lung tissues confirmed that
ERG was efficiently deleted in all vessels, including capillaries,
arteries and veins from ErgiEC-KO mice (Supplementary Fig. 11a,
b). CD31 (Fig. 8a, b), Isolectin B4 (Supplementary Fig. 11a, b) and
wheat germ agglutinin (WGA) (Supplementary Fig. 11c, d)
staining showed that despite some disruption of the vasculature
in both liver and lung, deletion of ERG did not lead to significant
loss of vascular coverage. TM protein levels were significantly
reduced in liver sinusoids (Fig. 8a, b) and lung capillaries (Fig. 8c,
d) from ErgiEC-KO mice.
Crucially, whilst ERG expression was also efficiently deleted in
EC lining the descending aorta (Supplementary Fig. 12a) of
ErgiEC-KO mice, TM expression was unchanged (Fig. 8e, f and
Supplementary Fig. 12a, b). These findings suggest that ERG
regulates TM expression specifically in microvascular beds
exposed to lower SS43,44 but not in EC of blood vessels (aorta)
exposed to high SS45,46.
In summary, this study identifies a vascular bed-specific anti-
thrombotic pathway, effective selectively in low SS conditions
and regulated by an ERG-KLF2 transcriptional complex. In the
lung and liver microvasculature exposed to lower SS, ERG
is required to provide access to chromatin and for KLF2-
dependent regulation of TM expression. In larger blood vessels
such as the aorta, high SS mediates epigenetic modifications,
increasing access to chromatin47; in this context, ERG becomes
dispensable for the regulation of TM. This double mechanism
may provide different levels of anti-thrombotic protection: a
baseline, plastic control in the microvasculature, where clot
formation may be required physiologically for vascular integrity,
and a higher level of control in large arteries, where the
formation of a single clot can be fatal. A diagram summarising
this model is shown in Fig. 9.
Discussion
In the present study, we identify a pathway that controls the anti-
thrombotic properties of the endothelium, via the transcription
factor ERG.
Previous studies have shown that ERG is required for main-
tenance of the endothelial lineage and to promote vascular
homeostasis, by controlling multiple functions including survival,
permeability and inflammation (reviewed previously27). Here, we
show that ERG also drives pathways that prevent spontaneous
clotting and thus exerts anti-thrombotic properties in EC. Other
TF have been reported to control pro- and anti-thrombotic
pathways, and their deletion or overexpression has been shown to
affect thrombus formation in a variety of in vivo injury models26.
However, the finding that loss of a single endothelial TF is
Fig. 4 ERG regulates thrombomodulin expression and activity in vitro. a qPCR analysis of thrombomodulin (TM) mRNA expression in control (siCtrl) and
ERG-deficient (siERG) HUVEC after 12, 24 and 48 h treatment (n= 3 independent experiments). Data were normalized to GAPDH. b Representative
immunoblot and quantification of TM following siCtrl or siERG treatment on HUVEC for 12, 24 and 48 h (n= 4 independent experiments). Data were
normalized to GAPDH. c Representative image and quantification of TM expression (green) in HUVEC transfected with siCtrl or siERG siRNA for 48 h by
immunofluorescence; nuclei are identified by DAPI (blue) and cells are co- stained for ERG (magenta). Scale bar 40 µm. Quantification represents the
mean pixel intensity for TM signal (arbitrary unit, A.U.) per cell. d, e Representative immunoblot and quantification of ERG and TM expression in control
(siCtrl) and ERG-deficient (siERG) d HDMEC (microvascular EC) or e HDBEC (microvascular EC) after 48 h siRNA treatment (n= 3). f qPCR analysis of
TM mRNA expression in HUVEC transfected with control pcDNA or ERG cDNA expression plasmid (ERG) (n= 3). Data were normalised to GAPDH.
g siCtrl or siERG-treated HUVEC for 48 h were incubated with protein C (300 nM), CaCl2 (5 mM), thrombin (10 nM). After 10, 20, 30 and 60min of
incubation at 37 °C, anti-thrombin III (100 nM) and heparin (15 U per ml) were added to neutralise thrombin, and protein C activity was measured using
chromogenic substrate S-2366 (0.5 mM) (n= 3). Data are expressed as relative activated protein C (APC) concentration normalised to siCtrl-treated
condition following 60min of incubation. All graphical data are mean ± s.e.m., *P < 0.05, **P < 0.01, ***P < 0.001, Student’s t-test. Source data are provided
as a Source Data file
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promoter-luciferase constructs (TM wild type (WT), TM mutant 1 or TM mutant 2) or a pGL4 empty vector in HUVEC, and luciferase activity was
measured. Values represent the fold change in relative luciferase activity over the empty pGL4 vector alone (n= 4 independent experiments). Graphical
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sufficient to cause spontaneous thrombosis is to our knowledge
unique, and in line with the essential role of ERG in maintaining
vascular homeostasis.
Multiple ERG targets are likely to be directly or indirectly
implicated in the control of coagulation. However, the gene target
consistently regulated by ERG across different tissues and in vitro
was the anticoagulant TM. Studies on the transcriptional reg-
ulation of TM have shown that KLF2 drives TM expression in
EC20, particularly under high laminar SS conditions21. In this
study, we show that ERG increases KLF2 binding to the TM
promoter by facilitating chromatin access via p300 recruitment
and H3K27 acetylation. We find that the ERG binding sites on
the proximal TM promoter are essential for ERG and KLF2-
dependent transactivation. These data suggest that both direct
cooperation between ERG and KLF2 and epigenetic regulation
controlled by ERG contribute to the fine regulation of TM
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expression in EC. A previous study reported cooperation between
ERG and KLF2 in driving Flk1 expression in Xenopus embryo.
Physical interaction between over-expressed ERG and KLF2 in a
non-EC line was described48, supporting our evidence of an
endogenous ERG-KLF2 interaction in EC.
In this study, we report a mechanism of differential tran-
scriptional control of TM expression depending on SS. We
show that ERG is essential for chromatin remodelling and for
KLF2-dependent regulation of TM selectively in low SS con-
ditions in vitro. Our findings suggest that ERG, together with
low levels of KLF2, provides the basal essential anticoagulant
properties required throughout the endothelium of the micro-
circulation; however, extra protection from unwanted thrombus
formation in a larger vessel, particularly arteries, is provided by
pathways induced by high laminar SS. Indeed, high SS has been
shown in vitro to promote endothelial epigenetic changes
leading to an increase in open and accessible chromatin47. This
could allow chromatin access for KLF2 and other TF to bind
DNA and drive gene expression, without requiring ERG. In line
with the concept of the additional KLF2-dependent protection,
Boon et al.49 have demonstrated that increased KLF2 expres-
sion in arterial high SS conditions results in activation of an
endothelial athero-protective phenotype, by inhibiting the
TGFβ-SMAD pathway. Interestingly, we have recently shown
that ERG represses the TGFβ-SMAD pathway in EC to prevent
endothelial-to-mesenchymal transition and fibrinogenesis36;
whether ERG and KLF2 also cooperate in the regulation of the
TGFβ pathway remains to be investigated. These studies suggest
a model of cooperation between ERG and KLF2 in the tran-
scriptional control of endothelial homeostasis, where ERG,
partly by promoting KLF2 binding to DNA, is essential to
maintain a basal, healthy and anti-thrombotic endothelium in
the microvasculature of multiple organs. This pathway appears
dispensable in blood vessels exposed to high SS, where the role
of KLF2 becomes dominant, and possibly other ETS factors
(such as ETS150) or other epigenetic mechanisms may step in to
provide cooperation. Future studies will investigate the TF
networks involved in shear-dependent, cooperative transcrip-
tional and epigenetic networks.
In vivo, endothelial deletion of KLF2 alone in adult mice does
not cause a spontaneous thrombotic phenotype; double deletion
of KLF2 and KLF4 is required to cause a profound compromise in
vascular integrity and dysregulation of the coagulation system26.
Crucially, deletion of endothelial ERG is sufficient to cause
thrombosis and coagulopathy, with decreased platelet counts,
decreased circulating levels of fibrinogen and increased D-dimer
and TAT plasma concentrations. The penetrance and severity of
the phenotype in ErgiEC-KO mice appears to be variable and
vascular bed-specific. In fact, the thrombotic and hemorrhagic
phenotypes observed in ErgiEC-KO mice occur selectively in the
liver and the lung, showing intriguing tissue-specificity of this
pathway. Our data also revealed an increased rate of thrombin
generation in ErgiEC-KO mice and an ERG-dependent regulation
of a set of genes potentially involved in the control of coagulation
(such as PAI1 and eNOS). Interestingly, acute treatment with a
red blood cells-targeted TM was able to restore the levels of TAT,
an early biomarker of coagulopathy and thrombosis, showing that
loss of TM expression is in part responsible for the prothrombotic
phenotype observed in ERG-deficient mice. Future experiments
will investigate the contribution of other pathways in the pro-
thrombotic phenotype of ErgiEC-KO mice.
Although regulation of TM expression is clearly a pivotal
mechanism through which ERG exerts its anti-thrombotic func-
tion, it is likely that the thrombotic phenotype caused by indu-
cible deletion of ERG results from a combination of pathways,
which may have different relevance depending on tissue-specific
mechanisms, still to be characterised. EC from different sites of
the vascular tree appear indeed to use a site-specific combination
of hemostatic proteins to prevent excessive clot formation4.
Specifically, the liver synthesizes and releases most of the proteins
involved in the clotting cascade (such as fibrinogen, protein C and
protein S)51. This high local concentration of coagulation factors
and the unique architecture of liver sinusoids, presenting fene-
strated and discontinuous EC52, might explain why the most
pronounced phenotype in ErgiEC-KO mice is observed in this
tissue. Moreover, one of ERG’s key function is to promote vas-
cular stability though the transcriptional control of genes, such as
VE-cadherin and claudin-527. Thus, it is possible that the
hemorrhagic phenotype, observed in the lung of adult ErgiEC-KO
mice, may be due to the combination of disrupted blood vessels
with increased permeability and impairment of coagulation,
leading to bleeding.
In conclusion, our study shows that ERG is crucial for the
maintenance of the endothelial anti-thrombotic environment.
We demonstrate that ERG is a direct transcriptional regulator
of TM, driving its expression in a context-specific manner by
cooperating with KLF2. The identification of vascular bed-
specific pathways has potentially important implications for
human pathologies, given that thrombotic diseases show
selective preferences for specific organs’ vascular beds. This
pathway could be involved in the pathogenesis of human dis-
ease associated with thrombosis in microvessels and/or with
coagulopathy, such as disseminated intravascular coagulation,
hemolytic uremic syndrome or sepsis.
Fig. 6 ERG cooperates with KLF2 to drive thrombomodulin expression. a–d TM promoter luciferase reporter assays. Values represent the fold change in
relative luciferase activity over the empty pGL4 vector alone. b pcDNA or ERG expression plasmid (ERG) were co-transfected with a TM wild type (WT)
promoter-luciferase construct (TM WT) in siCtrl or siKLF2-treated HUVEC, and luciferase activity was measured (n= 3 independent experiments). b
pcDNA or KLF2 cDNA expression plasmid (KLF2) were co-transfected with TM WT promoter construct in siCtrl or siERG-treated HUVEC (n= 3
independent experiments). Graphical data presented in a and b are mean ± s.e.m., *P < 0.05, **P < 0.01, Student’s t-test. c pcDNA, KLF2 or both KLF2 and
ERG plasmids were co-transfected with TM WT promoter construct (n= 4 independent experiments). Graphical data are mean ± s.e.m., ***P < 0.001,
****P < 0.0001, One-way ANOVA, compared to pcDNA-TM WT condition. d pcDNA or KLF2 plasmid were co-transfected with TM promoter constructs
(TM WT, TM mutant 1 or TM mutant 2) (n= 4 independent experiments). Graphical data are mean ± s.e.m., ***P < 0.001, ****P < 0.0001, One-way
ANOVA. ##P < 0.01, compared to pcDNA-TM WT, Student’s t-test. e, f ChIP-qPCR using primers to region R1 and R2 on e ERG- or f KLF2-bound
chromatin from siCtrl, siERG or siKLF2-treated HUVEC (n= 3 independent experiments). Primers for a region within 5’UTR region of TM gene (TM neg
con) were used as negative control. Data are shown as fold change over IgG. Graphical data are mean ± s.e.m., NS: Not Significant, *P < 0.05, **P < 0.01,
***P < 0.001, Student’s t-test. g Representative image of proximity ligation assay (PLA) for nuclear ERG-KLF2 interaction was performed on confluent
HUVEC using anti-ERG and anti-KLF2 antibodies; nuclei are identified by DAPI (blue). Scale bar, 20 μm. h Model: In homeostatic EC, ERG is required for
p300 recruitment at the TM promoter region, leading to acetylation of H3K27 which opens the chromatin and allows KLF2 binding to the TM promoter.
ERG binds to and cooperates with KLF2 to drive TM expression. In the absence of ERG, the chromatin is not accessible; KLF2 is not binding to the TM
promoter and is not able to transactivate the TM promoter. Source data are provided as a Source Data file
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Methods
Mice and breeding. All animal experiments were conducted according to and in
compliance with the guidelines from Directive 2010/63/EU of the European Par-
liament for animal testing and research, with ethical approval from Imperial
College London under UK Home Office Licence number PPL PEDBB/1586 and in
compliance with the UK Animals (Scientific Procedures) Act of 1986. The indu-
cible endothelial-specific ERG knockout mouse model (ErgiEC-KO) was generated
by breeding Ergfl/fl mice30,33 with Cdh5(PAC)-CreERT2 mice53; 10–12 weeks old
male and female mice were used for this study. Endothelial deletion of ERG was
induced in adult mice, between 6–8 weeks, by tamoxifen injection (five injections of
0.5 mg daily). All experiments were conducted using littermate controls; mice were
monitored, and tissues were harvested 25, 30 or 45 days post-tamoxifen injection.
Cell culture and flow experiments. Pooled human umbilical vein endothelial cells
(HUVEC) were purchased from Lonza (C2519A) (Wokingham, United Kingdom)
and cultured in Endothelial Cell Growth Medium-2 media (EGM-2) (Lonza) or
isolated from umbilical cords33,36 and cultured in M199 media. Human aortic
endothelial cells (HAEC) (single donor, Promocell, C-12271) were cultured in
EGM-2 media (Lonza). Human dermal microvascular endothelial cells (HDMEC)
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(HDMEC comprise blood and lymphatic microvascular endothelial cells; single
donor, Promocell, C-12212) and human dermal blood endothelial cells (HDBEC)
(HDBEC are only blood microvascular EC which are positive for CD31 and VWF
and negative for podoplanin; single donor, Promocell, C-12225) were cultured in
Endothelial Cell Media MV2 (Promocell). All endothelial cells were transfected
with plasmid or siRNA in EGM-2 media (Lonza). Cells were transfected with
siRNA against ERG exon6 or exon7 (siRNA #2) (20 nM), both denoted as siERG in
the text, and/or with siRNA against KLF2 (20 nM). An AllStars Negative Control
siRNA (Qiagen) was used, which is denoted as siCtrl. Sequences of the siRNA are
listed in Supplementary Table 1.
For flow experiments, transfected endothelial cells were re-plated after 24 h on
µ-slides I0.4 Luer-ibiTreat (ibidi) and placed under control static conditions, low (5
dynes per cm2) or high laminar shear stress (20 dynes per cm2) conditions for 24
hours using a parallel plate system (ibidi).
For some experiments, HUVEC were washed five times with starvation medium
(EBM2 (Lonza) supplemented with 1%-Bovine Serum Albumin (BSA)) and treated
with DMSO (Sigma) or C 646, p300/CBP Inhibitor (Abcam, ab142163) (5 or 10 µM)
for 1 or 4 h.
Immunoblotting analysis. Immunoblotting was performed according to standard
conditions and immunoblots were labelled with the primary antibodies listed in
Table 1. Primary antibodies were detected using fluorescently labelled secondary
antibodies: goat anti-rabbit IgG DyLight 680 and goat anti-mouse IgG Dylight 800
(Thermo Scientific). Detection of fluorescence intensity was performed using an
Odyssey CLx imaging system (Li-COR Biosciences, Lincoln) and Odyssey
ver.4 software. In some instances, primary antibodies were detected using HRP-
conjugated secondary antibodies: anti-rabbit (Cell Signalling, 7074S), anti-mouse
(GE HealthCare UK, NXA931V) and anti-goat (Dako, P0449). Fluorescence
intensity or chemiluminescence were quantified by densitometry using Fiji-ImageJ
software to measure protein levels and normalized against loading controls. The
primary antibodies used are listed in Table 1 and in Supplementary Table 2. See
source data file for the uncropped immunoblots.
Immunofluorescence analysis of HUVEC and mouse tissues. HUVEC for
immunofluorescence and PLA were fixed with 4% paraformaldehyde for 15 min-
utes and permeabilized with 0.5% Triton before blocking with 3% BSA. PLA was
performed according to the manufacturer’s instructions using the Duolink In Situ
Orange Kit Mouse/Rabbit (Sigma).
Tissues were fixed in 4% paraformaldehyde for 2 h and paraffin- (liver, lung) or
OCT-embedded (aorta). Sections were stained for hematoxylin/eosin or Masson’s
Trichrome or incubated with primary antibodies for immunofluorescence staining.
The primary antibodies used are listed in Table 1 and in Supplementary Table 2.
Nuclei were visualized using DAPI (4′,6-diamidino-2-phenylindole). Confocal
microscopy was carried out on a Carl Zeiss LSM780. Images were analysed with
ImageJ (NIH) and Volocity (Version 6.3, PerkinElmer).
Real-time polymerase chain reaction. Total RNA from tissues and HUVEC was
isolated by using the RNeasy kit (Qiagen) and reverse transcribed into cDNA using
Superscript III Reverse Transcriptase (Invitrogen).
Quantitative real-time PCR was performed using PerfeCTa SYBR Green
Fastmix (Quanta Biosciences) on a Bio-Rad CFX96 system. Gene expression values
were normalized to GAPDH expression (human) or 18s (mouse). See
Supplementary Tables 3 and 4 for the list of oligonucleotides.
Plasmids. Human ERG cDNA (NCBI Accession NM_182918) was cloned into the
mammalian vector pcDNA3.1 (Invitrogen). PpyCAG-KLF2-IB was a gift from
Austin Smith (Addgene plasmid # 60441; http://n2t.net/addgene:60441; RRID:
Addgene_60441)54. A 1.078 kb region of the TM promoter proximal to the TSS was
PCR amplified from human genomic DNA and cloned into the pGL4.10[luc2]
Luciferase Reporter Vector (Promega). See Supplementary Table 5 for oligonu-
cleotide sequences. pGL4.10[luc2] (Promega, Madison, USA) Firefly Luciferase
empty vector was used as a control. pGL4.74 [hRluc/TK] vector] (Promega) Renilla
luciferase vector was used as an internal control.
Multi site-directed mutagenesis. Mutation of the ERG binding sites (EBS) on the
thrombomodulin promoter luciferase construct (TM WT) was carried out using
QuikChange Lightning Multi Site-Directed Mutagenesis Kit (Agilent, Berkshire,
UK), according to the manufacturer’s instructions. Two AGGAA motifs were
changed to ACCAA to eliminate the ERG DNA binding motifs and generate the
thrombomodulin mutant 1 promoter (TM mut 1). In addition to these two
mutations, two other GGAA motifs were changed to CCAA and GCAA to generate
the thrombomodulin mutant 2 promoter (TM mut 2). Sequences of the mutagenic
oligonucleotides are listed in Supplementary Table 5.
Reporter assays. HUVEC were transfected with 1 µg of ERG plasmid or pcDNA3.1
empty vector and with luciferase reporter plasmids for 24 h using GeneJuice®
Transfection Reagent (Merck). Luciferase activity was measured using the Dual-
Luciferase Reporter Assay System (Promega) and a GloMax-Multi+Microplate
Multimode Reader (Promega). Luciferase reporter activity was normalized to the
internal Renilla luciferase control and is expressed relative to the pGL4 empty vector.
Chromatin immunoprecipitation-qPCR. Chromatin immunoprecipitation (ChIP)
was performed using the ChIP-IT Express kit (Active Motif)33, according to the
manufacturer’s instructions. In brief, HUVEC were cross-linked for 10min with 1%
formaldehyde. Chromatin was sheared using a Bioruptor UCD-200 ultrasound
sonicator (Diagenode) and immunoprecipitated with 3 μg antibody to ERG (sc-354X,
Santa Cruz Biotechnology), KLF2 (rabbit, ab203591, Abcam), H3K27Ac (rabbit,
39133, Active Motif) or p300 (mouse, ab14984, Abcam). The respective negative
controls were rabbit IgG (PP64, Chemicon, Millipore) and mouse IgG (12- 371,
Millipore). Immunoprecipitated DNA was then used as template for quantitative PCR
using primers specific for genomic loci and listed in Supplementary Table 5.
Bioinformatic analysis. ERG ChIP-sequencing data shown in this study can be
downloaded from the NCBI Gene Expression Omnibus (GEO) portal, accession
number GSE12489341. ERG transcription factor motif discovery was performed
using the JASPAR database (http://jaspar.genereg.net). Genome-wide ChIP-Seq
data for H3K27Ac and H3K4Me3 histone modifications, RNA polymerase II
occupancy in HUVEC and phyloP sequence conservation (plotted as conservation
scores −5/+5) were obtained from the Broad Institute and publicly available from
the ENCODE Consortium40. Tracks were visualized using the UCSC Genome
Browser database (https://genome.ucsc.edu/index.html).
Activated Protein C assay on HUVEC. HUVEC transfected with siRNA as
described above were re-seeded in a 24-well plate and Activated Protein C (APC)
assay was performed after 48 h of siRNA treatment. Cells were washed with assay
buffer (20 mM Tris, 100 mM NaCl, 1 mM CaCl2, 0.1% BSA, pH 7.5) and incubated
at 37 °C with human protein C (300 nM; Haematologic Technologies Inc. (HTI))
and human thrombin (10 nM; HTI). Samples were removed after 10, 20, 30 and 60
min and transferred to tubes containing human anti-thrombin III (100 nM; HTI)
and heparin (15U per mL).
For quantification of the APC generated, samples (100 µl) were transferred to a
96-well plate and S-2366 substrate (0.5 mM, Chromogenix) was added to the wells.
Cleavage of the substrate was measured at 405 nm for 20 min and the
concentration of APC was calculated compared to a standard curve derived from
pure APC with a known concentration (HTI). The concentrations were normalised
to the concentration of total protein for each well and expressed as percentage
compared to control siRNA following 60 min reaction time.
Fig. 7 ERG drives thrombomodulin expression in vitro selectively in low shear stress conditions. a Representative image and quantification of ERG (green)
and KLF2 (magenta) expression in HUVEC cultured under static conditions or exposed to low shear stress (LSS, 5 dynes per cm2) or high shear stress
(HSS, 20 dynes per cm2) for 24 h by immunofluorescence; nuclei are identified by DAPI (blue). Scale bar 40 µm. Quantification represents the mean pixel
intensity for ERG or KLF2 signal (arbitrary unit, A.U.) per cell (n= 3–4 images per condition). b Representative image of proximity ligation assay (PLA) for
nuclear ERG-KLF2 interaction was performed on confluent HUVEC cultured under static conditions or exposed to low shear stress (LSS, 5 dynes per cm2)
or high shear stress (HSS, 20 dynes per cm2) for 24 h; nuclei are identified by DAPI (blue). Quantification represents the PLA signal (mean number of dots
per cell) and is expressed as a percentage compared to static condition (n= 3–4 images per condition). Scale bar, 40 μm. c qPCR analysis of ERG, KLF2 and
TM mRNA expression in siCtrl or siERG-deficient HUVEC under static conditions or after 24 h under LSS or HSS (n= 4). d qPCR analysis of ERG, KLF2 and
TM mRNA expression in siCtrl or siERG-deficient HDBEC under static conditions or after 24 h under LSS or HSS (n= 3 independent experiments).
e Representative image and quantification of H3K27Ac expression (magenta) in siCtrl or siERG-deficient HUVEC cultured under static conditions or
exposed to LSS or HSS for 24 h by immunofluorescence; nuclei are identified by DAPI (blue). Scale bar 40 µm. Quantification represents the mean pixel
intensity for H3K27Ac signal (arbitrary unit, A.U.) per cell (n= 6 images per condition). All graphical data are mean ± s.e.m., *P < 0.05, **P < 0.01, ***P <
0.001, Student’s t-test for top panel and one-way Anova for bottom panel. Source data are provided as a Source Data file
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Hematologic analysis. Mice were anesthetised intraperitoneally with keta-
mine (75 mg per kg)/medetomidine (1 mg per kg) and bled from the retro-
orbital plexus into tubes containing 3.8% citrate anticoagulant. Platelet
counts were evaluated by flow cytometry using calibrated beads (Saxon Europe)
and rat anti-mouse GPIbβ-DyLight 488 (X488; Emfret) according to the
manufacturer’s instructions. Briefly, whole blood was diluted 1/20 with
modified Tyrode’s buffer and platelets were stained with rat anti-mouse
GPIbβ-DyLight 488 for 15 min at room temperature. Samples were analysed
using a FACSCalibur/LSRFortessa™ flow cytometer and Flowing Software
(v2.5.1).
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Fig. 8 ERG regulates thrombomodulin expression specifically in microvascular beds. a, c Representative image by immunofluorescence and
b, d quantification of TM expression (magenta) in a, b liver and c, d lung sections from Ergfl/fl and ErgiEC-KO mice 30 days after tamoxifen injection; tissues
are co-stained for CD31 to visualise blood vessels (green); nuclei are identified by DAPI (blue). Scale bar 50 µm. Quantification represents the ratio
between the sum of pixel intensity for TM signal (arbitrary unit, A.U.) and CD31 area (µm2) (reflecting vascular coverage) (n= 4 mice per genotype).
e Representative immunofluorescence image and f quantification of endothelial TM expression (magenta) in aorta sections from Ergfl/fl and ErgiEC-KO mice
45 days after tamoxifen injection; tissues are co-stained for ERG (green); nuclei are identified by DAPI (blue). Scale bar 50 µm. Quantification represents
the ratio between the sum of pixel intensity for TM signal (arbitrary unit, A.U.) and the number of EC per field identified by DAPI (n= 5 mice per
genotype). All graphical data are mean ± s.e.m., *P < 0.05, **P < 0.01, ***P < 0.001, Student’s t-test. Source data are provided as a Source Data file
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ELISA. Hemolytic plasma samples were excluded. Plasma levels of D-dimer,
Thrombin-antithrombin (TAT) and fibrinogen, were respectively determined using
a mouse D-dimer-ELISA kit (Clone Corp), a mouse TAT-ELISA kit (Abcam) and a
mouse fibrinogen ELISA kit (Abcam) according to the manufacturer’s instructions.
Samples were run in duplicate with n= 3–8 animals per group.
Thrombin generation assay. Thrombin generation in citrated mouse plasma was
assessed by calibrated automated thrombography (CAT)55,56. Briefly, single mouse
plasma preparations (40 µl per well) were used with 1 pM tissue factor (Dade
Innovin, Dade Behring), 4 µM phospholipid vesicles and 16.6 mM CaCl2. Contact
activation coagulation was inhibited by adding corn 2 trypsin inhibitor (65 µg
per ml plasma) and thrombin generation quantified by adding 0.42 mM of Z-
GlyArgAMC-HCl (Bachem). Samples were run in duplicate with n ≥ 4 animals
per group.
Production of mouse red blood cells-targeted thrombomodulin. Fusion protein
targeted to mouse glycophorin A was produced as described below39. Briefly, a
stable Drosophila S2 cell lines expressing red blood cells-targeted thrombomodulin
(RBC-TM) was maintained in Schneider’s medium (Thermo Fisher Scientific) and
transitioned to Insect-Xpress (Lonza, Walkersville, MD) for protein production.
Supernatants were harvested after induction with CuSO4. Protein also had a triple
FLAG and was purified using anti-FLAG (M2) affinity resin (Sigma-Aldrich) and
tested for purity via SDS-PAGE and HPLC (Waters, Huntingdon Valley, PA, USA)
using a Yarra™ 3 µm SEC-2000 LC Column 300 × 4.6 mm size exclusion column
with a flow rate of 0.35 mL per min (Phenomenex, Torrance, CA, USA). RBC-TM
migrated on SDS-PAGE as a single approximately 85 kDa band.
Characterization of RBC-TM in vitro. Characterization of the antithrombotic
properties of RBC-TM was assessed by performing APC generation assay in vitro.
Free RBC-TM (4 or 40 µg per ml) was incubated with 5 nM bovine thrombin
(Sigma-Aldrich, St Louis, MO) and 300 nM human protein C (Sigma-Aldrich, St
Louis, MO) for 20 min at room temperature. Thrombin was quenched with 50 U
per mL hirudin (Sigma-Aldrich, St Louis, MO), and APC was measured using APC
substrate S-2366 (Diapharma, West Chester, OH, USA). All samples were run in
quadruplicates. The rate of substrate hydrolysis was measured by monitoring the
change in absorbance at 405 nm over time at room temperature using a Spectramax
M2 Microplate reader (Molecular Devices, CA, USA). Data presented as maximum
signal reached at 20 min.
Acute treatment with RBC-TM in vivo. Endothelial deletion of ERG was induced
in adult mice (6 weeks) by tamoxifen injection. Twenty-four days post-tamoxifen
injection, mice were bled via the tail vein for analysis of hemostasis-related plasma
biomarkers (TAT, D-dimer and fibrinogen). The following day (25 days post
tamoxifen), mice were intravenously (tail vein) injected with RBC-TM (4 mg per
kg) and sacrificed 6 hours after this acute treatment. Mice were bled from the retro-
orbital plexus for plasma markers analysis and tissues were collected for histology.
Statistical analysis. All results presented in this study are representative of at least
three independent experiments. ‘n’ represents the number of biological replicates
unless otherwise stated. Data are shown as the mean ± standard error of the mean
(s.e.m.). Statistical significance was determined by two-tailed Student’s t test or
one-way ANOVA with Tukey post hoc test using Prism ver. 6.0 (GraphPad).
Differences were considered statistically significant with a P value < 0.05.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Data supporting the findings of this work are available within the paper and its
Supplementary Information file. The source data (included uncropped immunoblots)
underlying Figs. 1f–i, 2a–f, 3a–e, 4a–g, 5b–f, 6a–f, 7a–e, 8b, d, f and Supplementary
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Fig. 9 Distinct anti-thrombotic pathways in low versus high shear stress
conditions. Model of vascular bed-specific anticoagulant pathway effective
selectively in blood vessels exposed to low SS. Under low shear stress (SS),
EC express relatively low levels of KLF2 and TM. ERG is essential for p300
recruitment and basal acetylation of histone H3 (H3K27Ac), a marker of
open and accessible chromatin, and for KLF2 binding to the TM promoter,
and thus is required for basal TM expression in EC. The cooperativity
between ERG and KLF2 in driving TM expression maintains a basal anti-
thrombotic environment selectively in microvasculature beds exposed to
low SS. In contrast, high laminar SS mediates epigenetic modifications,
including increased H3K27Ac levels, through different pathways, leading to
an increase in open and accessible chromatin allowing transcription factors
binding. KLF2 expression is also induced in this context and drives
increased levels of TM, providing an additional protective mechanism in
blood vessels (aorta and arteries) where thrombosis can be fatal. ERG is
dispensable for this regulation; other transcription factors may cooperate
with KLF2 to drive TM level in high shear stress conditions
Table 1 Complete list of antibodies used for this study
Antibody (host) Company Catalogue number Application and dilution
CD31 (rabbit) Abcam ab28364 IF (mouse tissue, 1/200)
CD41 [MWReg30] (rat) Abcam ab33661 IF (mouse tissue, 1/200)
Isolectin B4 (IB4) Vector FL-1201 IF (mouse tissue,1/200)
Wheat Germ Agglutinin (WGA) Thermo Fisher Scientific W11261 IF (mouse tissue, 1/400)
ERG (mouse) Santa Cruz sc-376293 PLA (HUVEC, 1/200)/WB (HUVEC, 1/2000)
ERG (rabbit) Abcam ab133264 IF (HUVEC, 1/200)/WB (HUVEC, 1/1000)
ERG (rabbit) Abcam ab92513 IF (mouse tissue, 1/200)/WB (mouse tissue, 1/1000)
Fibrinogen (rabbit) Abcam ab34269 IF (mouse tissue, 1/200)
GAPDH (mouse) Millipore MAB374 WB (HUVEC, mouse tissue, 1/10000)
H3K27Ac (rabbit) Active Motif 39133 IF (HUVEC, 1/200)
KLF2 (rabbit) Abcam ab203591 PLA (HUVEC, 1/100)/WB (HUVEC, 1/500)
Actin, α-smooth muscle-Cy3 (mouse) Sigma C6198 IF (mouse tissue, 1/400)
TM (mouse) Dako Clone 1009 IF (HUVEC, 1/100)
TM (mouse) Santa Cruz sc-13164 WB (HUVEC, 1/1000)
TM (goat) R&D AF3894 IF (mouse tissue, 1/200)/WB (mouse tissue, 1/1000)
List of antibodies used for immunofluorescence (IF), western blot (WB) and proximity ligation assay (PLA). Dilution of the antibodies used for each specific application is specified in the right column (in
brackets)
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Figs. 1a, b, d–h, 3a, 4a–h, 7a, b, 8a, c–h, 9c and 10 are provided as a Source Data file. Any
other data are available from the corresponding authors upon reasonable request.
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